184 related articles for article (PubMed ID: 1651160)
1. Phase I trial of intravenous infusion of ex-vivo-activated autologous blood-derived macrophages in patients with non-small-cell lung cancer: toxicity and immunomodulatory effects.
Faradji A; Bohbot A; Schmitt-Goguel M; Roeslin N; Dumont S; Wiesel ML; Lallot C; Eber M; Bartholeyns J; Poindron P
Cancer Immunol Immunother; 1991; 33(5):319-26. PubMed ID: 1651160
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of liposomal MTP-PE-activated autologous monocytes administered intraperitoneally to patients with peritoneal carcinomatosis.
Faradji A; Bohbot A; Frost H; Schmitt-Goguel M; Siffert JC; Dufour P; Eber M; Lallot C; Wiesel ML; Bergerat JP
J Clin Oncol; 1991 Jul; 9(7):1251-60. PubMed ID: 2045866
[TBL] [Abstract][Full Text] [Related]
3. Adoptive transfer of tumor cytotoxic macrophages generated in vitro from circulating blood monocytes: a new approach to cancer immunotherapy.
Andreesen R; Scheibenbogen C; Brugger W; Krause S; Meerpohl HG; Leser HG; Engler H; Löhr GW
Cancer Res; 1990 Dec; 50(23):7450-6. PubMed ID: 1701343
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of adoptive immunotherapy of cancer patients using monocyte-derived macrophages activated with interferon gamma and lipopolysaccharide.
Hennemann B; Beckmann G; Eichelmann A; Rehm A; Andreesen R
Cancer Immunol Immunother; 1998 Jan; 45(5):250-6. PubMed ID: 9439648
[TBL] [Abstract][Full Text] [Related]
5. Local immunostimulation induced by intravesical administration of autologous interferon-gamma-activated macrophages in patients with superficial bladder cancer.
Pagès F; Lebel-Binay S; Vieillefond A; Deneux L; Cambillau M; Soubrane O; Debré B; Tardy D; Lemonne JL; Abastado JP; Fridman WH; Thiounn N
Clin Exp Immunol; 2002 Feb; 127(2):303-9. PubMed ID: 11876754
[TBL] [Abstract][Full Text] [Related]
6. A new approach to adoptive immunotherapy of cancer using tumorcytotoxic macrophages grown from peripheral blood monocytes.
Andreesen R; Scheibenbogen C; Brugger W; Krause S; Leser HG; Kopf S; Engler H; Schümichen C; Löhr GW
Cancer Detect Prev; 1991; 15(5):413-21. PubMed ID: 1751953
[TBL] [Abstract][Full Text] [Related]
7. Adoptive immunotherapy with activated macrophages grown in vitro from blood monocytes in cancer patients: a pilot study.
Lopez M; Fechtenbaum J; David B; Martinache C; Chokri M; Canepa S; De Gramont A; Louvet C; Gorin I; Mortel O
J Immunother (1991); 1992 Apr; 11(3):209-17. PubMed ID: 1515425
[TBL] [Abstract][Full Text] [Related]
8. Hemostatic changes in human adoptive immunotherapy with activated blood monocytes or derived macrophages.
Wiesel ML; Faradji A; Grunebaum L; Bohbot A; Schmitt-Goguel M; Bergerat JP; Cazenave JP; Oberling F
Ann Hematol; 1992 Aug; 65(2):75-8. PubMed ID: 1324742
[TBL] [Abstract][Full Text] [Related]
9. Production of macrophage-activated killer cells for targeting of glioblastoma cells with bispecific antibody to FcgammaRI and the epidermal growth factor receptor.
Wallace PK; Romet-Lemonne JL; Chokri M; Kasper LH; Fanger MW; Fadul CE
Cancer Immunol Immunother; 2000 Nov; 49(9):493-503. PubMed ID: 11092616
[TBL] [Abstract][Full Text] [Related]
10. Phase I/II trial of autologous activated macrophages in advanced colorectal cancer.
Eymard JC; Lopez M; Cattan A; Bouché O; Adjizian JC; Bernard J
Eur J Cancer; 1996 Oct; 32A(11):1905-11. PubMed ID: 8943673
[TBL] [Abstract][Full Text] [Related]
11. Modulation of monocyte activation in patients with rheumatoid arthritis by leukapheresis therapy.
Hahn G; Stuhlmüller B; Hain N; Kalden JR; Pfizenmaier K; Burmester GR
J Clin Invest; 1993 Mar; 91(3):862-70. PubMed ID: 8450066
[TBL] [Abstract][Full Text] [Related]
12. Apheresis-elutriation program for adoptive immunotherapy with autologous activated monocytes in cancer patients.
Faradji A; Bohbot A; Schmitt-Goguel M; Dumont S; Eischen A; Wiesel ML; Stierle A; Follea G; Eber M; Bergerat JP
Int J Artif Organs; 1991 May; 14(5):304-12. PubMed ID: 1864656
[TBL] [Abstract][Full Text] [Related]
13. Adoptive immunotherapy with tumor-cytotoxic macrophages derived from recombinant human granulocyte-macrophage colony-stimulating factor (rhuGM-CSF) mobilized peripheral blood monocytes.
Hennemann B; Rehm A; Kottke A; Meidenbauer N; Andreesen R
J Immunother; 1997 Sep; 20(5):365-71. PubMed ID: 9336743
[TBL] [Abstract][Full Text] [Related]
14. Clinical and immunomodulatory effects of combination immunotherapy with low-dose interleukin 2 and tumor necrosis factor alpha in patients with advanced non-small cell lung cancer: a phase I trial.
Yang SC; Grimm EA; Parkinson DR; Carinhas J; Fry KD; Mendiguren-Rodriguez A; Licciardello J; Owen-Schaub LB; Hong WK; Roth JA
Cancer Res; 1991 Jul; 51(14):3669-76. PubMed ID: 1648441
[TBL] [Abstract][Full Text] [Related]
15. Recombinant human interferon-beta (rHuIFN-beta) and radiation therapy for inoperable non-small cell lung cancer.
Byhardt RW; Vaickus L; Witt PL; Chang AY; McAuliffe T; Wilson JF; Lawton CA; Breitmeyer J; Alger ME; Borden EC
J Interferon Cytokine Res; 1996 Nov; 16(11):891-902. PubMed ID: 8938564
[TBL] [Abstract][Full Text] [Related]
16. Prospective phase II study of post-surgical adjuvant chemo-immunotherapy using autologous dendritic cells and activated killer cells from tissue culture of tumor-draining lymph nodes in primary lung cancer patients.
Kimura H; Iizasa T; Ishikawa A; Shingyouji M; Yoshino M; Kimura M; Inada Y; Matsubayashi K
Anticancer Res; 2008; 28(2B):1229-38. PubMed ID: 18505060
[TBL] [Abstract][Full Text] [Related]
17. Biological and clinical effects of the combination of beta- and gamma-interferons administered as a 5-day continuous infusion.
Schiller JH; Storer B; Witt PL; Nelson B; Brown RR; Horisberger M; Grossberg S; Borden EC
Cancer Res; 1990 Aug; 50(15):4588-94. PubMed ID: 2114942
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration.
Kleinerman ES; Jia SF; Griffin J; Seibel NL; Benjamin RS; Jaffe N
J Clin Oncol; 1992 Aug; 10(8):1310-6. PubMed ID: 1634921
[TBL] [Abstract][Full Text] [Related]
19. Production of human macrophages with potent antitumor properties (MAK) by culture of monocytes in the presence of GM-CSF and 1,25-dihydroxy vitamin D3.
Chokri M; Lopez M; Oleron C; Girard A; Martinache C; Canepa S; Siffert JC; Bartholeyns J
Anticancer Res; 1992; 12(6B):2257-60. PubMed ID: 1295473
[TBL] [Abstract][Full Text] [Related]
20. Comparison of interleukin-12 with lung cancer and malignant lymphoma undergoing autologous peripheral blood stem cell transplantation.
Yoshimura C; Nomura S; Kanazawa S; Kuwana M; Yamaguchi K; Fukuhara S
J Cancer Res Clin Oncol; 2002 Jan; 128(1):29-36. PubMed ID: 11862469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
